Global Psoriasis Drugs Market Size, Share, Analysis, Industry Report and Forecast 2019-2025

The global psoriasis drug market is expected to grow at a significant CAGR during the forecast period. The market is segmented on the basis of drug class and route of administration. Based on the drug class, the market is segmented into TNF inhibitors, interleukin inhibitors, vitamin D analogs, and others. Based on the route of administration, the market is segmented into oral, parenteral, and topical.

To Request a Sample of our Report on Global Psoriasis Drugs Market: https://www.omrglobal.com/request-sample/psoriasis-drugs-market

There is an array of topical and systemic drug therapies that are optimized in such a way to gain optimal benefit and compliance. Treatment for each patient is customized in such a way to reduce adverse effects, based on the patient’s drug history, existing quality of life, caregiver situation, self-care capability, financial needs and feasibility for the treatment. Initially, the treatment is usually started with economical therapies and then intensified to newer and advanced ones until an acceptable and effective therapy is reached with good compliance. Some of the most common drugs preferred for the treatment include corticosteroids and vitamin D analogs.

Corticosteroids are the most commonly prescribed medications for treating mild to moderate psoriasis. It aids in slowing down the cell turnover by suppressing the immune system, which reduces inflammation and itching. Low-potency corticosteroid ointments are usually recommended for sensitive areas such as the face or skin folds, and for treating widespread patches of damaged skin. Adverse effects seen are thinning of the skin, telangiectasia, and systemic side effects such as diabetes, hypertension, and HPA suppression. Some of the corticosteroids used are clobetasol propionate 0.05%, amcinonide 0.1%, betamethasone dipropionate, betamethasone valerate as 0.1%, 0.12% and 1%, halcinonide 0.1%, Desoximetasone 0.25% and mometasone furoate.

Vitamin D Analogues – Vitamin D analogs (calcitriol and calcipotriene) have emerged as important alternatives to topical corticosteroids for the long-term therapy of psoriasis. They bind to cytoplasmic Vitamin D Receptor then translocate into the nucleus, where they bind to the nuclear receptor and commence the transcription of vitamin D responsive genes. These transcription proteins then regulate cell differentiation and downregulate cell proliferation and inflammatory processes associated with this condition. They are considered a safe alternative, despite causing perilesional irritation and erythema.

They may rarely increase serum and urine calcium levels, so the total concentration per week should not exceed 100 gm. Calcitriol is a more potent analog but calcipotriene is the most established one. Calcipotriene has shown to affect calcium homeostasis to a very lesser extent. Most trials have shown that combination treatment of vitamin D and a corticosteroid was usually more effective than monotherapy with either used alone.

Additionally, some other drug class that is utilized in the psoriasis treatment includes TNF Inhibitors, Interleukin Inhibitors, among others offered by the key players. The key players operating in the global psoriasis drugs market is also driving the market growth. Players such as AbbVie, Inc., Amgen Inc., Eli Lilly and Co., Johnson & Johnson Services Inc., Novartis International AG, AstraZeneca Plc, Boehringer Ingelheim International GmbH, Pfizer, Inc., and Sun Pharmaceutical Industries Ltd., are significantly contributing to the growth of the global psoriasis drugs industry by adopting various growth strategies.

Product launches & developments, partnerships, agreements, and acquisitions are among some of the strategies adopted by the players to sustain in a competitive Psoriasis Drugs market during the forecast period. For instance, in August 2019, Amgen Inc. announced to pay $13.4 billion for a blockbuster psoriasis drug from Celgene Corp., which is shedding the asset to win antitrust regulators’ sign-off for Celgene’s $74-billion merger with Bristol-Myers Squibb Co.

(Get 15% Discount on Buying this Report)
A full Report of Global Psoriasis Drugs Market is Available at: https://www.omrglobal.com/industry-reports/psoriasis-drugs-market
Global Psoriasis Drugs Market – Segmentation

By Drug Class

• TNF Inhibitors
• Interleukin Inhibitors
• Vitamin D Analogs
• Others

By Route of Administration

• Oral
• Parenteral
• Topical

Regional Analysis

North America

• United States
• Canada

Europe

• UK
• Germany
• Spain
• France
• Italy
• Rest of Europe

Asia-Pacific

• India
• China
• Japan
• Rest oF APAC

Rest of The World

Company Profiles

• AbbVie, Inc.
• Amgen Inc.
• AstraZeneca Plc
• Bausch Health Companies Inc.
• Biogen, Inc.
• Boehringer Ingelheim International GmbH
• Celltrion Healthcare Co. Ltd.
• Dr. Reddy's Laboratories Ltd.
• Eli Lilly and Co.
• Johnson & Johnson Services Inc.
• LEO Pharma A/S
• Merck & Co. Inc.
• Novartis International AG
• Pfizer, Inc.
• Sun Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Co. Ltd.
• UCB SA

Reasons to Buying From us –
1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/psoriasis-drugs-market

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.